Safety and Effectiveness of Hylan G-F 20 Post-Arthroscopic Meniscectomy in Knee OA

Overview

This prospective multicenter study evaluated the safety and efficacy of a single intra-articular injection of hylan G-F 20 in patients with mild to moderate knee osteoarthritis (OA) experiencing pain 4-12 weeks after arthroscopic meniscectomy. The study demonstrated that hylan G-F 20 is a safe and effective treatment option for symptomatic relief in this patient population.

Background

Osteoarthritis is a common degenerative joint disorder causing pain and functional impairment, particularly in the knee. Arthroscopic meniscectomy is often performed for meniscal tears in OA patients unresponsive to conservative treatments, but its clinical benefit remains controversial. Persistent pain after meniscectomy is common, and viscosupplementation with hyaluronic acid derivatives like hylan G-F 20 is an established treatment for knee OA. However, its use specifically after arthroscopic meniscectomy has been less studied.

Data Highlights

Patients were enrolled at 10 centers across Europe with mild to moderate knee OA (Kellgren-Lawrence grade I or II). Inclusion required pain scores between 50-90 mm on visual analogue scales 4-12 weeks post-meniscectomy. A single 2 ml intra-articular injection of hylan G-F 20 was administered. Baseline radiological severity and surgical procedures were documented, with mean time from meniscectomy to injection of 53 days (range 27–107 days).

Key Findings

• Hylan G-F 20 was administered safely with no major adverse events reported.
• Patients showed symptomatic improvement in knee pain and global assessment scores following injection.
• Inclusion criteria ensured patients had mild to moderate OA (Kellgren-Lawrence grade I or II) and persistent pain despite meniscectomy.
• Arthrocentesis was performed prior to injection to remove effusion, optimizing treatment conditions.
• No corticosteroids or other viscosupplements were used within 3 months prior to study entry, isolating the effect of hylan G-F 20.

Clinical Implications

Hylan G-F 20 can be considered a safe and effective option for patients with mild to moderate knee OA who continue to experience pain after arthroscopic meniscectomy. Its use may provide symptomatic relief and potentially delay the need for more invasive interventions such as total knee replacement. Careful patient selection and adherence to injection protocols are important to optimize outcomes.

Conclusion

This study supports the use of hylan G-F 20 viscosupplementation as a valuable treatment for persistent knee OA pain following arthroscopic meniscectomy, demonstrating favorable safety and efficacy profiles in this specific patient group.

References

1. Moseley et al. 2002 -- Randomized Trial of Arthroscopic Surgery for Osteoarthritis of the Knee
2. Marshall 2005 -- Retrospective Study of Hylan G-F 20 Post-Arthroscopic Debridement
3. Professional Guidelines 2000s -- Treatment of Knee Osteoarthritis